Autolus Therapeutics plc (NASDAQ:AUTL) Given Consensus Rating of "Buy" by Analysts

Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $9.32.

AUTL has been the topic of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Truist Financial reduced their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, Wells Fargo & Company reduced their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in shares of Autolus Therapeutics during the 4th quarter valued at $26,000. Barclays PLC grew its stake in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after buying an additional 10,866 shares in the last quarter. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the 4th quarter worth $35,000. Arkadios Wealth Advisors purchased a new position in shares of Autolus Therapeutics during the 4th quarter worth about $47,000. Finally, Invesco Ltd. boosted its stake in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Trading Down 6.3%

Shares of AUTL stock traded down $0.09 during mid-day trading on Friday, reaching $1.27. The stock had a trading volume of 478,182 shares, compared to its average volume of 1,458,885. The stock's 50-day moving average price is $1.51 and its two-hundred day moving average price is $2.21. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $5.00. The firm has a market capitalization of $336.67 million, a PE ratio of -1.05 and a beta of 1.77.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million. On average, equities research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.